• Explore /
  • Poster
  • / Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).

Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).

Abstract Poster

Authors

null

Dieter Koeberle

Claraspital, Basel, Switzerland

Dieter Koeberle , Jean-Francois Dufour , Gyula Demeter , Panagiotis Samaras , Piercarlo Saletti , Qiyu Li , Arnaud Roth , Daniel Horber , Michael Buehlmann , Anna Dorothea Wagner , Michael Montemurro , Gabor Lakatos , Karin Ribi , Jonas Feilchenfeld , Markus Peck-Radosavljevic , Daniel Rauch , Ivana Cvijetic , Britta Tschanz , Gyorgy Bodoky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01005199

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4099)

DOI

10.1200/jco.2014.32.15_suppl.4099

Abstract #

4099

Poster Bd #

186

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Jaekyung Cheon

First Author: Dongming Liu

Poster

2022 ASCO Gastrointestinal Cancers Symposium

BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial).

BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial).

First Author: Kristen Renee Spencer